Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis
Anti-M3R antibodies are associated with a more severe GI phenotype and distinct extraintestinal and serological features in SSc patients. Utilizing these features may optimize risk stratification in clinical practice and identify those likely to have progressive GI disease for clinical trials.
Authors
- Ami A. Shah (ORCID: https://orcid.org/0000-0002-1139-2009)
- Laura K. Hummers (ORCID: https://orcid.org/0000-0002-4864-4011)
- Michael Hughes (ORCID: https://orcid.org/0000-0003-3361-4909)
- Mark Pimentel (ORCID: https://orcid.org/0000-0002-0619-5115)
- Zsuzsanna H. McMahan (ORCID: https://orcid.org/0000-0001-6461-8940)
- Ali Yağiz Ayla (ORCID: https://orcid.org/0000-0003-2581-7992)
- Walter Morales
- Naveen R Kalavar
Institutions
- Cedars-Sinai Medical Center (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Manchester (GB)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1093/rheumatology/keaf197
- Citations
- 8
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 11.77